S&P 500   4,591.67
DOW   35,227.03
QQQ   386.20
S&P 500   4,591.67
DOW   35,227.03
QQQ   386.20
S&P 500   4,591.67
DOW   35,227.03
QQQ   386.20
S&P 500   4,591.67
DOW   35,227.03
QQQ   386.20

Sarepta Therapeutics Insider Trades

+3.20 (+4.08%)
(As of 12/6/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
818,697 shs
Average Volume
1.30 million shs
Market Capitalization
$7.11 billion
P/E Ratio
Dividend Yield

Sarepta Therapeutics (NASDAQ:SRPT) Insider Buying and Selling Activity

Insider Ownership

Number Of
Insiders Buying
(Last 12 Months)

Amount Of
Insider Buying
(Last 12 Months)
$2.30 M

Number Of
Insiders Selling
(Last 12 Months)

Amount Of
Insider Selling
(Last 12 Months)
$1.63 M

Skip Chart & View Insider Trade History

Insider Buying and Selling by Quarter

Get SRPT Insider Trade Alerts

Want to know when executives and insiders are buying or selling Sarepta Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

Sarepta Therapeutics (NASDAQ SRPT) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/24/2021Louise Rodino-KlapacInsiderBuy3,780$79.33$299,867.40  
11/17/2021Douglas S IngramCEOBuy25,026$79.94$2,000,578.44  
3/10/2021M Kathleen BehrensDirectorSell5,000$85.76$428,800.00135,517  
3/8/2021Hans Lennart Rudolf WigzellDirectorSell10,000$83.51$835,100.0026,518  
12/11/2020Joseph BraticaInsiderSell1,115$165.00$183,975.009,255  
12/8/2020Joseph BraticaInsiderSell1,125$160.00$180,000.00  
8/10/2020Hans Lennart Rudolf WigzellDirectorSell10,000$159.00$1,590,000.0023,792  
8/7/2020Richard BarryDirectorSell30,000$158.50$4,755,000.003,132,280  
8/3/2020Joseph BraticaInsiderSell1,125$155.00$174,375.008,957  
6/22/2020David T HowtonEVPSell105,122$170.88$17,963,247.3633,151  
5/20/2020Hans Lennart Rudolf WigzellDirectorSell5,000$150.64$753,200.0018,792  
5/15/2020Richard BarryDirectorSell30,000$141.26$4,237,800.003,163,813  
3/4/2020Hans Lennart Rudolf WigzellDirectorSell5,000$116.89$584,450.0018,792  
12/13/2019Alexander CumboEVPSell42,000$125.50$5,271,000.0013,888  
12/13/2019Sandesh MahatmeCFOSell125,000$125.50$15,687,500.0034,498  
11/22/2019David T HowtonEVPSell25,000$105.00$2,625,000.0024,388  
9/13/2019Richard BarryDirectorBuy5,000$87.49$437,450.003,183,756  
9/9/2019Michael W BonneyDirectorBuy2,000$86.74$173,480.007,051  
9/6/2019M Kathleen BehrensDirectorBuy2,500$87.98$219,950.00123,167  
8/20/2019Richard BarryDirectorBuy5,000$99.32$496,600.003,182,065  
8/14/2019Richard BarryDirectorBuy3,700$122.50$453,250.003,177,065  
8/12/2019Douglas S IngramCEOBuy16,252$123.07$2,000,133.64424,405  
8/12/2019Richard BarryDirectorBuy1,300$122.50$159,250.003,173,365  
5/23/2019Hans Lennart Rudolf WigzellDirectorSell10,000$120.00$1,200,000.0021,717  
2/7/2019Sandesh MahatmeCFOSell65,000$145.00$9,425,000.0073,649  
2/1/2019David T HowtonSVPSell30,000$140.00$4,200,000.0031,196  
1/31/2019Sandesh MahatmeCFOSell65,000$130.23$8,464,950.0014,118  
11/1/2018Hans Lennart Rudolf WigzellDirectorSell6,667$140.50$936,713.50126,534  
10/30/2018Douglas S IngramCEOBuy16,695$120.39$2,009,911.05412,811  
10/24/2018Sandesh MahatmeCFOSell107,524$127.74$13,735,115.7648,381  
8/15/2018Douglas S IngramCEOBuy16,000$125.26$2,004,160.00399,250  
7/16/2018David T HowtonSVPSell50,000$136.46$6,823,000.0037,967  
7/9/2018Alexander CumboSVPSell33,782$137.32$4,638,944.2440,690  
6/27/2018Richard BarryDirectorSell75,000$130.34$9,775,500.003,170,432  
11/30/2017Hans Lennart Rudolf WigzellDirectorSell6,667$55.89$372,618.6313,333  
11/8/2017Douglas S IngramCEOBuy38,138$52.44$1,999,956.72420,196  
11/6/2017Shamim RuffSVPSell10,000$55.00$550,000.0037,045  
10/3/2017Shamim RuffSVPSell11,500$50.00$575,000.00  
7/27/2017Douglas S IngramCEOBuy47,058$42.50$1,999,965.00382,058  
7/21/2017Shamim RuffSVPSell12,138$42.97$521,569.8627,312  
7/20/2017Alexander CumboSVPSell5,918$41.00$242,638.0022,793  
7/20/2017Edward M Md KayeDirectorSell10,000$41.00$410,000.0062,471  
7/20/2017Sandesh MahatmeCFOSell50,000$41.00$2,050,000.0041,736  
10/17/2016Sandesh MahatmeInsiderSell30,000$50.08$1,502,400.0061,532  
9/22/2016David T HowtonSVPSell7,000$60.00$420,000.0028,453  
9/22/2016Edward M Md KayeCEOSell40,179$60.00$2,410,740.00117,162  
9/19/2016David T HowtonSVPSell9,304$50.00$465,200.0011,168  
9/19/2016Edward M Md KayeCEOSell24,352$50.00$1,217,600.0089,983  
9/19/2016Jayant AphaleVPSell35,000$50.00$1,750,000.0021,490  
9/14/2016Edward M Md KayeCEOSell24,557$30.00$736,710.0076,983  
3/16/2016M Kathleen BehrensDirectorBuy10,000$14.54$145,400.00112,166  
3/14/2016M Kathleen BehrensDirectorBuy65,000$16.54$1,075,100.00112,166  
11/14/2013Anthony ChaseDirectorBuy10,000$13.95$139,500.0041,744  
9/16/2013M Kathleen BehrensDirectorBuy6,500$37.04$240,760.0044,166  
9/3/2013John HodgmanDirectorSell5,556$34.97$194,293.32  
8/22/2013Anthony ChaseDirectorBuy3,500$32.68$114,380.0031,744  
8/20/2013Sandesh MahatmeCFOBuy5,000$31.10$155,500.005,000  
6/14/2013Anthony R ChaseDirectorBuy10,000$38.50$385,000.00  
9/7/2012M Kathleen BehrensDirectorBuy17,500$14.73$257,775.00  
(Data available from 1/1/2013 forward)

Sarepta Therapeutics (NASDAQ:SRPT) Insider Trade Frequently Asked Questions

Who is on Sarepta Therapeutics's Insider Roster?

The list of insiders at Sarepta Therapeutics includes Alexander Cumbo, David T Howton, Douglas S Ingram, Hans Lennart Rudolf Wigzell, Joseph Bratica, Louise Rodino-Klapac, M Kathleen Behrens, Michael W Bonney, Richard Barry, and Sandesh Mahatme.Learn more on SRPT's insiders

What percentage of Sarepta Therapeutics stock is owned by insiders?

5.90% of Sarepta Therapeutics stock is owned by insiders. Learn more on SRPT's insider holdings

Which Sarepta Therapeutics insiders have been buying company stock?

The following insiders have purchased Sarepta Therapeutics stock in the last 24 months: Douglas S Ingram ($2,000,578.44), and Louise Rodino-Klapac ($299,867.40).

How much insider buying is happening at Sarepta Therapeutics?

Insiders have purchased a total of 28,806 Sarepta Therapeutics shares in the last 24 months for a total of $2,300,445.84 bought.

Which Sarepta Therapeutics insiders have been selling company stock?

The following insiders have sold Sarepta Therapeutics stock in the last 24 months: Alexander Cumbo ($5,271,000.00), David T Howton ($17,963,247.36), Hans Lennart Rudolf Wigzell ($3,762,750.00), Joseph Bratica ($538,350.00), M Kathleen Behrens ($428,800.00), Richard Barry ($8,992,800.00), and Sandesh Mahatme ($15,687,500.00).

How much insider selling is happening at Sarepta Therapeutics?

Insiders have sold a total of 370,487 Sarepta Therapeutics shares in the last 24 months for a total of $52,644,447.36 sold.

This page was last updated on 12/7/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.